Vontobel Holding Ltd. Has $226,000 Position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Vontobel Holding Ltd. reduced its stake in shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 34.9% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 15,500 shares of the company’s stock after selling 8,300 shares during the period. Vontobel Holding Ltd.’s holdings in Day One Biopharmaceuticals were worth $226,000 as of its most recent SEC filing.

A number of other hedge funds have also modified their holdings of DAWN. Arizona State Retirement System grew its stake in shares of Day One Biopharmaceuticals by 8.2% in the 4th quarter. Arizona State Retirement System now owns 13,373 shares of the company’s stock valued at $195,000 after buying an additional 1,010 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its stake in Day One Biopharmaceuticals by 352.2% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,067 shares of the company’s stock valued at $147,000 after acquiring an additional 7,841 shares during the last quarter. Legato Capital Management LLC grew its position in Day One Biopharmaceuticals by 14.3% in the fourth quarter. Legato Capital Management LLC now owns 41,918 shares of the company’s stock worth $612,000 after acquiring an additional 5,242 shares in the last quarter. SG Americas Securities LLC increased its stake in shares of Day One Biopharmaceuticals by 74.9% during the 4th quarter. SG Americas Securities LLC now owns 64,692 shares of the company’s stock worth $945,000 after purchasing an additional 27,712 shares during the last quarter. Finally, Exchange Traded Concepts LLC raised its holdings in shares of Day One Biopharmaceuticals by 34.0% during the 4th quarter. Exchange Traded Concepts LLC now owns 10,072 shares of the company’s stock valued at $147,000 after purchasing an additional 2,554 shares in the last quarter. 87.95% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

DAWN has been the topic of several analyst reports. HC Wainwright reissued a “buy” rating and set a $50.00 target price on shares of Day One Biopharmaceuticals in a research report on Wednesday. The Goldman Sachs Group lowered their price objective on Day One Biopharmaceuticals from $50.00 to $44.00 and set a “buy” rating on the stock in a report on Tuesday, February 27th. Wedbush restated an “outperform” rating and issued a $33.00 target price on shares of Day One Biopharmaceuticals in a report on Wednesday. Needham & Company LLC increased their price target on Day One Biopharmaceuticals from $30.00 to $33.00 and gave the company a “buy” rating in a report on Wednesday. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Day One Biopharmaceuticals from $32.00 to $36.00 and gave the stock an “overweight” rating in a research note on Monday. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $39.33.

Day One Biopharmaceuticals Stock Down 8.7 %

Shares of DAWN stock opened at $15.19 on Thursday. Day One Biopharmaceuticals, Inc. has a 12 month low of $9.67 and a 12 month high of $17.85. The firm has a market cap of $1.33 billion, a PE ratio of -6.38 and a beta of -1.48. The stock has a 50 day moving average of $15.28 and a 200-day moving average of $13.79.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing the consensus estimate of ($0.57) by ($0.07). As a group, equities analysts predict that Day One Biopharmaceuticals, Inc. will post -2.66 EPS for the current fiscal year.

Insider Activity at Day One Biopharmaceuticals

In related news, insider Samuel C. Blackman sold 10,000 shares of the business’s stock in a transaction dated Thursday, April 18th. The stock was sold at an average price of $16.02, for a total transaction of $160,200.00. Following the transaction, the insider now directly owns 1,174,662 shares in the company, valued at $18,818,085.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Samuel C. Blackman sold 10,000 shares of the firm’s stock in a transaction on Thursday, April 18th. The stock was sold at an average price of $16.02, for a total value of $160,200.00. Following the completion of the transaction, the insider now directly owns 1,174,662 shares of the company’s stock, valued at $18,818,085.24. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Samuel C. Blackman sold 2,258 shares of the business’s stock in a transaction on Friday, February 16th. The shares were sold at an average price of $15.25, for a total transaction of $34,434.50. Following the completion of the sale, the insider now directly owns 1,244,662 shares in the company, valued at approximately $18,981,095.50. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 55,781 shares of company stock worth $883,160. Company insiders own 8.40% of the company’s stock.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.